A Phase I Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma

Trial Profile

A Phase I Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Nov 2016

At a glance

  • Drugs Ipilimumab (Primary) ; Melphalan
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Nov 2016 Planned End Date changed from 1 Jun 2017 to 1 Jun 2020.
    • 23 Nov 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2020.
    • 23 Nov 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top